Djakovic Z, Djakovic I, Cesarec V, Madzarac G, Becejac T, Zukanovic G, et al
Record whether the symptom began immediately after the injection, later that evening, or on the following day
This shift has two major implications for organizations that operate at the intersection of value-based care and complex chronic disease management: Medicaid wants outcomes, not procedures
Phase 3 clinical trials demonstrated a significant reduction in visceral fat without major metabolic side effects (Falutz et al., J Clin Endocrinol Metab 2010)
A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine
Anti-obesity drugs: past, present and future